Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)
Por:
Capdevila, J, Hernando, J, Molina-Cerrillo, J, Viñuales, MB, Garcia-Carbonero, R, Teulé, A, Custodio, A, Jimenez-Fonseca, P, Lopez, C, Hierro, C, Carmona-Bayonas, A, Alonso, V, Llanos, M, Sevilla, I, García-Alvarez, A, Alonso-Gordoa, T, Jiménez, IG, Anton-Pascual, B, Sánchez, AM and Grande, E
Publicada:
14 nov 2025
Resumen:
Purpose: Multikinase inhibitors have shown efficacy in endocrine neoplasms, and synergism with immune checkpoint inhibitors has been noted in other tumors.Patients and Methods: This is a prospective, multicenter, open-label, Simon two-stage optimal design, phase II study including patients with advanced and refractory endocrine and neuroendocrine neoplasms in six cohorts: lung well-differentiated neuroendocrine tumors, anaplastic thyroid cancer (ATC), adrenocortical carcinoma (ACC), pheochromocytoma/paraganglioma (PPGL), well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET), and grade 3 extrapulmonary neuroendocrine neoplasms. Patients received atezolizumab 1,200 mg intravenously every 3 weeks plus cabozantinib 40 mg/day orally until disease progression or unacceptable toxicity. The primary objective was the overall response rate (ORR) by RECIST 1.1.Results: From October 2020 to December 2022, 93 patients were included. The ORR was 14.3% [95% confidence interval (CI), 1.8-42.8] in ATC (N = 14); 8.3% (95% CI, 1.0-27.0) in ACC (N = 24); 15.4% (95% CI, 1.9-45.5) in PPGL (N = 13), and 16.7% (95% CI, 4.7-37.4) in GEP-NET (N = 24). Lung well-differentiated neuroendocrine tumors and grade 3 extrapulmonary neuroendocrine neoplasms had no responses. The duration of response was 20.4 months in ATC, 13.1 months in ACC, 12.2 months in PPGL, and 15.8 months in GEP-NET. Survival rates at 12 months in ATC and ACC were 47.6% and 47.6%, respectively. No unexpected toxicity was observed.Conclusions: Cabozantinib and atezolizumab were safely administered and showed promising ORR, and preliminary long-term survival rates were observed in aggressive and pretreated ACC and ATC, which warrants further investigation.
Filiaciones:
Capdevila, J:
Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Med Oncol Dept, Barcelona, Spain
Hernando, J:
Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Med Oncol Dept, Barcelona, Spain
Molina-Cerrillo, J:
Hosp Univ Ramon y Cajal, Med Oncol Dept, Madrid, Spain
Viñuales, MB:
Univ Hosp Virgen Rocio, Med Oncol Dept, Inst Biomed Sevilla IBIS, Seville, Spain
Garcia-Carbonero, R:
UCM, Hosp Univ 12 Octubre, Imas12, Med Oncol Dept,Fac Med, Madrid, Spain
Teulé, A:
Inst Catala Oncol ICO IDIBELL, Med Oncol Dept, Barcelona, Spain
Custodio, A:
Hosp Univ La Paz, Med Oncol Dept, IdiPAZ, Madrid, Spain
Jimenez-Fonseca, P:
Hosp Univ Cent Asturias, Med Oncol Dept, ISPA, Oviedo, Spain
Lopez, C:
Hosp Univ Marques de Valdecilla, Med Oncol Dept, IDIVAL, Santander, Spain
:
Catalan Inst Oncol ICO Badalona, Badalona Appl Res Grp Oncol B ARGO, Med Oncol Dept, Badalona, Spain
Carmona-Bayonas, A:
UMI, Hosp Univ Morales Meseguer, IMIB, Hematol & Med Oncol Dept, Murcia, Spain
Alonso, V:
Hosp Univ Miguel Servet, Med Oncol Dept, Inst Aragones Invest Sanitaria, Zaragoza, Spain
Llanos, M:
Hosp Univ Canarias, Med Oncol Dept, San Cristobal De La Lagun, Spain
Sevilla, I:
Hosp Univ Reg & Virgen Victoria Malaga, Med Oncol Dept, Invest Clin & Traslac Canc, Inst Invest Biomed Malaga IBIMA, Malaga, Spain
García-Alvarez, A:
Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Med Oncol Dept, Barcelona, Spain
Alonso-Gordoa, T:
Hosp Univ Ramon y Cajal, Med Oncol Dept, Madrid, Spain
Jiménez, IG:
Univ Hosp Virgen Rocio, Med Oncol Dept, Inst Biomed Sevilla IBIS, Seville, Spain
Anton-Pascual, B:
Hosp Univ Ramon y Cajal, Med Oncol Dept, Madrid, Spain
Sánchez, AM:
UCM, Hosp Univ 12 Octubre, Imas12, Med Oncol Dept,Fac Med, Madrid, Spain
Grande, E:
MD Anderson Canc Ctr Madrid, Med Oncol Dept, C Arturo Soria 270, Madrid 28033, Spain
Green Submitted, hybrid
|